ACC CardiaCast

PulseCheck" is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This series, published during Peripheral Artery Disease (PAD) Awareness Month, is in collaboration with the ACC's Vascular Disease Section. In this episode, Andrea Price, MS, AACC hosts Hussein Abu Daya MD, FACC, Brian Rose, PA-C, MPH, AACC and Bailey Estes MSN, AGNP-C, to begin the PAD series with an introductory overview.

"Courtside with the Chair" is a new series within CardiaCast presented by the Sports and Exercise Cardiology Member Section covering topics within the field of sports and exercise cardiology. In this "Part 2" episode, Dr. Jonathan Kim continues the conversation with Drs. Michael Ackerman, Rachel Lampert, and Matthew Martinez of the "how to" and approach to shared decision-making in the context of sports participation for athletes with heart disease. Suggested Materials: (You can include formal references external to ACC.org here. Please list numerically as formal citations. Example: Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail 2017;23:464-75). Subscribe to CardiaCast | Claim CME Credit

In this episode, Drs. Erin Michos and Steven Nissen discuss newly emerging therapies for elevated Lp(a) management and forthcoming developments in research. Drs. Michos and Nissen highlight the key differences between therapies in late trial stages and discuss upcoming cardiovascular outcome trials. This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here! Suggested Materials: Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18:100651. Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92. Reyes-Soffer G, Ginsberg HN, Berglund L, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. ArteriosclerThromband Vasc Biol 2022;42:e48-e60. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;18:e308-e319. Subscribe to CardiaCast | More information on Elevating Lp(a) HERE

"Courtside with the Chair" is a new series within CardiaCast presented by the Sports and Exercise Cardiology Member Section covering topics within the field of sports and exercise cardiology. In this episode, Dr. Jonathan Kim is joined by Drs. Michael Ackerman, Rachel Lampert, and Matthew Martinez to discuss the "why" and "how to" related to shared decision-making in the context of sports participation for athletes with heart disease. Subscribe to CardiaCast | Claim CME Credit

"PulseCheck" is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This episode is an update to the March 2024 PulseCheck: Shared Decision Making podcast in which host Andrea Price MS, AACC brings together Liz Perpetua ARNP, ACNP-BC, DNP, FACC, Martha Gulati MD, MS, FACC, and Bailey Estes MSN, AGNP-C, to explore best practices related to structural heart disease. Dr. Perpetua, the chair and lead author of JACC Advances Expert Panel Perspective: Shared Decision-Making in Multidisciplinary Team-Based Cardiovascular Care, offers insights from the July 2024 publication. Subscribe on iTunes | Subscribe on Google Play |

In this episode, Drs. Erin Michos and Gissette Reyes-Soffer discuss how clinicians can manage elevated Lp(a) by treating all modifiable factors in patients. The global risk assessment of patients and what can be done now to navigate and mitigate risk is also addressed. This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here! Suggested Materials: Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol 2024;18:100651. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48-e60. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;Mar 29:[ePub ahead of print]. Subscribe to CardiaCast | More information on Elevating Lp(a) HERE

In this episode, Drs. Erin Michos and Christie Ballantyne examine the importance of testing and identifying lipoprotein(a) ( Lp[a]) levels in patients, research highlighting trends in populations at risk, and the genetic factors involved in assessment. The significance associated with various levels of Lp(a) in measurement and how testing plays a role in management is also discussed. This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!

In this episode, Drs. Maya Guglin, Nikhil Narang, Dustin Hillerson, Anju Bhardwaj, and Megan Pelter will delve into recently published randomized controlled clinical trials on venoarterial extracorporeal membrane oxygenation (VA-ECMO). They will cover trials on cardiogenic shock, including the ECMO-CS multicenter randomized trial, and discuss findings from the EVOLVE-ECMO trial on left ventricular venting.

In this episode of CardiaCast, world-renowned hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will review changes occurring in the field of HCM and explore best practice recommendations from the newly issued guideline, 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. This podcast is part of the 2024 Update to the AHA/ACC HCM Guidelines: Expert Interpretation for Application to Practice grant initiative presented by ACCF and Med-IQ.

"Heart Vision" is a new CardiaCast podcast series stemming from the ACC Cardiovascular Imaging Section Leadership Council. This podcast series will tackle topics on emerging multimodality imaging data, trends, practice patterns, disease status and advocacy effort. In this episode, Drs. Purvi Parwani and Christopher Kramer will discuss the main imaging highlights from 2024 Guideline for the Management of Hypertrophic Cardiomyopathy.